Evidence map›Paper›PMID 38020903›Full record

ArticleFrontiers in cell and developmental biology2023

Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies.

Ester Fagnano, Swati Pendharkar, Madyson Colton, Philip N Jones, Marta Crespi Sallan, Tetyana Klymenko, Andrejs Braun, Christian Klein, Jamie Honeychurch, Eleanor J Cheadle and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Ester FagnanoTargeted Therapy Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.
Swati PendharkarTargeted Therapy Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.
Madyson ColtonTargeted Therapy Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.
Philip N JonesTargeted Therapy Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.
Marta Crespi SallanCentre for Haemato-Oncology, John Vane Science Centre, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Tetyana KlymenkoDepartment of Biosciences and Chemistry, Sheffield Hallam University, Sheffield, United Kingdom.
Andrejs BraunCentre for Haemato-Oncology, John Vane Science Centre, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Christian KleinRoche Innovation Center Zurch, Roche Glycart AG, Schlieren, Switzerland.
Jamie HoneychurchTargeted Therapy Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.
Eleanor J Cheadle *Targeted Therapy Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.
Timothy M Illidge *Targeted Therapy Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.
Cancer Research UK Manchester Institute · GBUniversity of Manchester · GBQueen Mary University of London · GBRoche (Switzerland) · CHSheffield Hallam University · GB

Funding

Cancer Research UK 21022Cancer Research UK 28280
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antibodyCD20lymphomastromatumor microenvironment

Identifiers

PMID38020903
PMCPMC10646167
OpenAlexW4388042471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.